small molecule

CRENESSITY

CRINECERFONT

Loss of exclusivityJanuary 2043latest FDA-listed patent expiry

CompanyNeurocrine Biosciences →See this company's full patent-cliff portfolio

Drug detail

Brand name	CRENESSITY
Active ingredient	CRINECERFONT
Strength	100MG
Dosage form	CAPSULE
Route	ORAL
Modality	Small molecule
FDA approval	December 2024
Marketing status	RX

Listed patents

Patent	Expires	Type
12582634	January 2043	substance
12128033	June 2041	substance
10905690	January 2035	use U-4049
11311544	January 2035	use U-4049
11730739	January 2035	use U-4049

Regulatory exclusivity

Code	Expires
ODE-503	December 2031
NCE	December 2029

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Neurocrine Biosciences